News

Applications are open for the MedTech Innovator Competition 2021 »

MedTech Innovator is the largest accelerator of medical devices in the world. We provide an unparalleled platform to support startups with the access, visibility, and network to bring their innovations to patients. Our alumni have raised over $2B in follow-on funding, brought 75 products to the market, and achieved 11 acquisitions. In its latest CipherBio report, Silicon Valley Bank recognized MTI as having the most active fundraising portfolio in 2020 of any accelerator.

Applications are open for the 2021 program. This is a highly selective and unique opportunity for startups and scale-ups to be showcased and gain access to healthcare stakeholders including investors, customers, and industry leaders such as Johnson & Johnson, Baxter, Olympus, W. L. Gore, Nipro, Edwards Lifesciences, Dexcom, Asahi Intecc, Fujikura, Jabil Healthcare, Maxim Integrated Products, and others. This year, up to $500,000 in non-dilutive prizes will be awarded.

Showcase at Leading Industry Conferences

Among other benefits, companies selected for the 2021 program will receive showcase presentation slots and one complimentary registration to the MedTech Innovator Summit and WSGR Medical Device Conference in June as well as The MedTech Conference powered by AdvaMed in September.

Prizes

Compete for up to $500,000 in non-dilutive cash prizes and in-kind awards

Who Should Apply?

All early to mid-stage medical device, diagnostic, or digital health companies are encouraged to apply. Preference for the Accelerator program will be given to companies that have not yet raised a Series B. All companies are eligible for the Showcase program.

Companies do not need to relocate to participate. MedTech Innovator does not charge or take equity for participation, and there is no application fee.

Apply Now

Recent News

11/21/2025

A new era of global growth: George Mason and Naugen launch international innovation accelerator

This month, a new Northern Virginia International Soft-Landing Accelerator (NISA) program, designed to help start-ups from around the globe find guidance, connections, and lab or office spaces at no cost, was launched to help develop new technologies in life sciences.Applications are now open for the first NISA cohort. Participants in the six-month program will have

11/20/2025

VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future

A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia’s life sciences ecosystem, higher-ed universities, and community colleges on October 31. This

11/11/2025

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Specifically, a rapamycin loading concentration of 4% w/w has been achieved for Quoin’s proprietary topical